The kidney transplant study evaluates safety and pharmacokinetics in patients with BK virus infection, which has no approved antiviral treatment.

Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "BK Virus Infection Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...

Asahi Kasei Therapeutics announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561 ...

The Company announced the development of the first antiviral to combat BK virus, one of the most common viral infections in transplant patients CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics ...

Many health conditions that appear in adulthood can sometimes be traced back to infections acquired early in life. One example gaining scientific attention is the BK virus, a common childhood ...

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of ...

PARIS--(BUSINESS WIRE)--SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal ...

PARIS--(BUSINESS WIRE)-- SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal ...

Orthogon Therapeutics, a developer of novel antiviral medicines, today announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M.